Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
The group could soon provide clarity on CTX112’s regulatory path.
